𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of parkinson’s disease

✍ Scribed by Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E. Gross; Erwan Bezard

Book ID
111640695
Publisher
Springer
Year
2003
Tongue
English
Weight
258 KB
Volume
28
Category
Article
ISSN
0893-7648

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Topiramate reduces levodopa-induced dysk
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease
✍ Monty A. Silverdale; S.L. Nicholson; A.R. Crossman; J.M. Brotchie 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic actio

Pharmacological characterization of psyc
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Naomi P. Visanji; Jordi Gomez-Ramirez; Tom H. Johnston; Donna Pires; Valerie Voo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

## Abstract Investigation of the pathophysiology of psychosis in Parkinson's disease (PD), as well as the assessment of potential novel therapeutics, has been limited by the lack of a well‐validated animal model. MPTP‐lesioned primates exhibit abnormal behaviors that are distinct from dyskinesia an

The selective mu-opioid receptor antagon
The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease
✍ James B. Koprich; Susan H. Fox; Tom H. Johnston; Allan Goodman; Bertrand Le Bour 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

## Abstract In Parkinson's disease (PD), dyskinesia develops following long‐term treatment with 3,4‐dihydroxyphenylalanine (L‐dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the